NCT03021330View on ClinicalTrials.gov

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

May 15, 2026

Study Completion Date

October 15, 2027

Conditions
AML
Interventions
DRUG

Daunomycin and Cytarabine (DA Regimen)

"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."

DRUG

Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)

"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER